The reiteration of a Market Outperform rating and a $24 price target by a JMP Securities analyst could positively influence investor sentiment towards Ocular Therapeutix, potentially driving up its stock price in the short term. The analyst's endorsement serves as a strong signal of confidence in the company's future performance.